Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del
Authors
Keywords
-
Journal
Journal of Cystic Fibrosis
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-02-27
DOI
10.1016/j.jcf.2023.02.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of CFTR modulator therapy on cystic fibrosis-related diabetes
- (2021) Holly Gaines et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Rapid Improvement After Starting Elexacaftor-tezacaftor-ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
- (2021) Pierre-Régis Burgel et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
- (2021) Patrick A Flume et al. Lancet Respiratory Medicine
- Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease
- (2021) Bermingham B et al. Journal of Cystic Fibrosis
- Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
- (2021) Sivagurunathan Sutharsan et al. Lancet Respiratory Medicine
- MS1 VALIDATION OF MODELED 5-YEAR SURVIVAL OUTCOMES AMONG PATIENTS WITH CYSTIC FIBROSIS (CF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) IVACAFTOR USING US CF FOUNDATION PATIENT REGISTRY (USCFFPR) DATA
- (2020) L. Mcgarry et al. VALUE IN HEALTH
- Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis
- (2020) Sanja Stanojevic et al. Journal of Cystic Fibrosis
- Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries
- (2019) Nataliya Volkova et al. Journal of Cystic Fibrosis
- WS12-3 Real-world outcomes among patients with cystic fibrosis treated with lumacaftor/ivacaftor (LUM/IVA) in 2017: an interim analysis of data from the US CF Foundation Patient Registry (CFFPR)
- (2019) C. Knox et al. Journal of Cystic Fibrosis
- The future of cystic fibrosis care: a global perspective
- (2019) Scott C Bell et al. Lancet Respiratory Medicine
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
- (2019) Harry G M Heijerman et al. LANCET
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
- (2019) Peter G. Middleton et al. NEW ENGLAND JOURNAL OF MEDICINE
- High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis
- (2018) Christine Rousset-Jablonski et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations
- (2018) Denis Hadjiliadis et al. GASTROENTEROLOGY
- Triplet CFTR modulators: future prospects for treatment of cystic fibrosis
- (2018) Nauman Chaudary Therapeutics and Clinical Risk Management
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
- (2017) Jennifer L. Taylor-Cousar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study
- (2017) Michael W Konstan et al. Lancet Respiratory Medicine
- Cystic fibrosis: a clinical view
- (2016) Carlo Castellani et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment
- (2016) Donald R. VanDevanter et al. Journal of Cystic Fibrosis
- Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data
- (2015) Gregory S. Sawicki et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
- (2015) Claire E. Wainwright et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis
- (2014) Penny Whiting et al. HEALTH TECHNOLOGY ASSESSMENT
- Cystic fibrosis
- (2009) Brian P O'Sullivan et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started